This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Trading Biotech With Options: Exelixis

I expect Exelixis shares to continue trading between $4 and $6 (but mostly around or below $5) before November expiration (Nov. 17) due to the back-and-forth selling and buying pressure between underwater shareholders, convertible bondholders and new speculators.

Investors can take advantage of this Exelixis situation by executing the following options trade:

Sell (10) NOV 4.0 strike Puts at 0.35 = $(350)
Buy 10 NOV 4.0 strike Calls at 0.75 = $750
Sell (20) NOV 5.0 strike Calls at 0.30 = $(600)
Buy 10 NOV 6.0 strike Calls at 0.15 = $150

Trade Initial P&L = $(50) Credit

This is a Credit Call Butterfly -- that is, I am actually being paid to put on this position (not much, $50 for this size, but still being paid nevertheless.) The position involves buying a Call Butterfly (see above) and selling a Put to fully finance the cost. The key risk is obviously to the downside since we sold the Put. Unless negative data comes out prior to November option expiration -- or the company unexpectedly announces a delay or other negative news -- I would expect Exelixis' share price to remain above $4 given the impending Nov. 29 FDA drug approval decision date.

Obviously, I could be wrong. Maximum profit for this trade size is $1,050 if the shares trade to $5 by expiration and this profit tapers off between $4 and $6. (See the P&L diagram.)

If the stock trades below $4 by Nov. 17 expiration I will be assigned the shares (1,000 shares for this size trade) and be positioned to either hold into the possible run-up, sell 4.0 strike DEC Calls against the shares (i.e. trade into a covered Call) or simply remove any risk and sell them.

Pelz is currently long Exelixis shares.

Follow Tony Pelz on Twitter.

Stock quotes in this article: EXEL 
Tony Pelz was a trader on a major European bank's proprietary trading desk, responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Pelz worked with several global investment banks in roles ranging from corporate finance, M&A to credit and business development. He is author of The Biotech Trader Handbook, 2nd Edition, co-founder of the small-cap biotech research and trading site Chimera Research Group and operator of Pelz currently resides in Denver, Colorado where he trades for his own account.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs